Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...

REDEFINE 2 is evaluating CagriSema in type 2 diabetes patients who are also either obese or overweight. Novo Nordisk’s CEO Lars Fruergaard Jorgensen said the company “remains confident in ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call ... The presentation is structured as outlined on Slide 2. Please note that all sales and operating profit growth statements ...

Shares of Novo Nordisk (NYSE: NVO ... The leg up comes as the S&P 500 (SNPINDEX: ^GSPC) gained 0.2%, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.1% on the day. The pharmaceutical giant ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...